Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
| Autor: | Anthony S. David, Bernard Lachaux, Peter Molcan, Ilse Augustyns, Lars Eriksson, Pierre Chue, Mariëlle Eerdekens, H. Pretorius |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Adolescent Drug Administration Schedule law.invention Randomized controlled trial Double-Blind Method law Oral tablets Long acting risperidone medicine Humans Pharmacology (medical) Adverse effect Biological Psychiatry Aged Pharmacology Psychiatric Status Rating Scales Risperidone Positive and Negative Syndrome Scale Dose-Response Relationship Drug business.industry Drug Administration Routes Middle Aged medicine.disease Clinical trial Psychiatry and Mental health Treatment Outcome Neurology Schizophrenia Anesthesia Delayed-Action Preparations Female Neurology (clinical) business medicine.drug Antipsychotic Agents |
| Zdroj: | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 15(1) |
| ISSN: | 0924-977X |
| Popis: | A double-blind study of long-acting injectable risperidone and oral risperidone tablets was conducted in 640 patients with schizophrenia. All patients received flexible doses of 1-6 mg of oral risperidone for 8 weeks. Doses were stable during weeks 5-8. At the end of week 8, symptomatically stable patients were randomly assigned to receive long-acting risperidone (active injections, dummy oral) or continued oral risperidone (dummy injections, active oral) for 12 weeks. Significant improvements were demonstrated from baseline to endpoint in Positive and Negative Syndrome Scale (PANSS) total (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect